Increased Severe Cases and New-Onset Type 1 Diabetes Among Children Presenting With Diabetic Ketoacidosis During First Year of COVID-19 Pandemic in Turkey.

Introduction: There have been some significant changes regarding healthcare utilization during the COVID-19 pandemic. Majority of the reports about the impact of the COVID-19 pandemic on diabetes care are from the first wave of the pandemic. We aim to evaluate the potential effects of the COVID-19 pandemic on the severity of diabetic ketoacidosis (DKA) and new onset Type 1 diabetes presenting with DKA, and also evaluate children with DKA and acute COVID-19 infection. Methods: This is a retrospective multi-center study among 997 children and adolescents with type 1 diabetes who were admitted with DKA to 27 pediatric intensive care units in Turkey between the first year of pandemic and pre-pandemic year. Results: The percentage of children with new-onset Type 1 diabetes presenting with DKA was higher during the COVID-19 pandemic (p < 0.0001). The incidence of severe DKA was also higher during the COVID-19 pandemic (p < 0.0001) and also higher among children with new onset Type 1 diabetes (p < 0.0001). HbA1c levels, duration of insulin infusion, and length of PICU stay were significantly higher/longer during the pandemic period. Eleven patients tested positive for SARS-CoV-2, eight were positive for new onset Type 1 diabetes, and nine tested positive for severe DKA at admission. Discussion: The frequency of new onset of Type 1 diabetes and severe cases among children with DKA during the first year of the COVID-19 pandemic. Furthermore, the cause of the increased severe presentation might be related to restrictions related to the pandemic; however, need to evaluate the potential effects of SARS-CoV-2 on the increased percentage of new onset Type 1 diabetes.

COVID-19 Transmission and Clinical Features in Pediatric Intensive Care Health Care Workers.

OBJECTIVE: This study aims to investigate modes of transmission and clinical features of coronavirus disease 2019 in healthcare workers in pediatric intensive care units. MATERIALS AND METHODS: This multicenter descriptive study was conducted between March and November 2020. Patient demographics, clinical characteristics, origin of coronavirus disease 2019, treatment modalities, and loss of workdays were recorded. RESULTS: Seven hundred and sixty-eight healthcare workers from 16 pediatric intensive care units were enrolled and 114 (14.8%) healthcare workers with a mean age of 29.7 ± 6.7 years became coronavirus disease 2019 patients. Seventy-six (66.7%) patients were female. Approximately half (54.3%) of the patients were physicians, 34.2% were nurses, and 11.4% were ancillary staff. Transmission was deemed to occur through patient contact in 54.3% of the patients. Comorbid illness was present 10.5% of the patients. Transmission occurred during endotracheal intubation in 21%, cardiopulmonary resuscitation in 9.6%, and non-invasive ventilation in 12.2% of patients, while transmission was a result of multiple possible procedures in 43.8%. Intensive care admission was needed for 13.1% of the patients. Five patients needed oxygen by cannula, 7 needed oxygen with a non-rebreathing mask, 5 needed high-flow nasal cannula support, 5 needed non-invasive ventilation, and 3 needed invasive mechanical ventilation. Fortunately, no infected healthcare workers died. CONCLUSION: Coronavirus disease 2019 in healthcare workers is a significant problem in pediatric intensive care units. Transmission seems to occur particularly frequently during patient care procedures such as intubation, ventilation and aerosol therapy, which highlights the importance of proper use of full sets of personal protective equipment during all procedures during care of coronavirus disease 2019 patients.

The relationship of abdominal perfusion pressure with mortality in critically ill pediatric patients.

PURPOSE: To the best of our knowledge, in the literature, there is no data regarding clinical utility of the abdominal perfusion pressure (APP) in critically ill children. Thus, in the present study, we aimed to investigate the clinical utility of APP in predicting of survival in critically ill children with IAH. DESIGN: A prospective cohort study of patients between 1 month to 18 years who had risk for intra-abdominal hypertension from June 2013 to January 2014. SETTING: Pediatric intensive care unit (PICU) at a tertiary university hospital. PATIENTS: Thirty-five (16 female) PICU patients who had risk for the development of IAH were included. Serial intraabdominal pressure (IAP) and mean arterial pressure (MAP) measurements were performed. Abdominal perfusion pressure was calculated using the formula (MAP-IAP). MEASUREMENTS AND MAIN RESULTS: Overall mortality rate was 49% (n = 17). The mortality rate in patients with IAP mean ≥10 mmHg (n = 27, 77%) was 55% (n = 15), while 53% (n = 16) in patients with IAP max ≥10 mmHg (n = 30, 86%) and 47% (n = 7) in patients with IAP min ≥ 10 mmHg (n = 15, 43%). Overall mean APP was 58 ±â€¯20 mmHg. Logistic regression analysis revealed that decrease in minAPP was associated with increased risk for mortality (Odds ratio for each 1 mmHg decrease in APP was 1.052 [CI 95%, 1.006-1.100], p < 0.05). ROC curve analysis revealed that, in predicting mortality, area under curve for minAPP was 0.765. The optimal cut-off point for APP was obtained as 53 mmHg with the 77.8% sensitivity and 70.6% specificity using the IU method. CONCLUSIONS: Our findings showed that APP seems to be a useful tool in predicting mortality. Interventions to improve APP may be associated with better outcomes in critically ill PICU patients. LEVEL OF EVIDENCE: Level II. TYPE OF STUDY: Diagnostic.

Serum, urine, and saliva levels of ghrelin and obestatin pre- and post-treatment in pediatric epilepsy.

INTRODUCTION: In this study, we aimed to determine the serum, urine, and saliva levels of acyl ghrelin, des-acyl ghrelin, and obestatin in the newly diagnosed idiopathic generalized pediatric epilepsy patients in the pretreatment period and in the third month of valproic acid. MATERIAL AND METHODS: Thirty pre- and post-treatment cases of patients who were diagnosed with idiopathic generalized epilepsy and 30 control patients were included in this study. Serum, saliva, and urine levels of ghrelin were measured in epileptic group and in the control group in the pretreatment period and in the third month of the treatment. RESULTS: There were 14 females and 16 males. Mean age was 8.9 ± 2.5 years. Mean body mass index was 17.2 ± 2.3 in the patients and 16.6 ± 2.0 in the control group, whereas it was 16.8 ± 2.1 in the third month of the therapy (P > 0.05). Pretherapy serum, urine, and saliva levels of acyl ghrelin were 36.45 ± 9.93, 31.78 ± 12.87, and 34.23 ± 11.49 pg/mL, respectively in the patient group. Post-treatment serum, urine, and saliva levels of acyl ghrelin were 51.34 ± 12.01, 48.24 ± 16.76, and 44.90 ± 14.99 pg/mL in the patient group. Pretherapy serum, urine, and saliva levels of des-acyl ghrelin were 419.62 ± 75.63, 370.59 ± 60.11, and 396.28 ± 60.76 pg/mL, respectively in the patient group. Post-therapy serum, urine, and saliva levels of des-acyl ghrelin were 458.61 ± 87.10, 429.92 ± 55.81, and 449.48 ± 74.32 pg/mL, respectively in the patient group. Pretherapy serum, urine, and saliva levels of obestatin were 23.02 ± 3.15, 14.27 ± 4.22, and 29.52 ± 5.39 ng/mL, respectively. Post-therapy serum, urine, and saliva levels of obestatin were 24.30 ± 4.18, 15.27 ± 6.43, and 30.94 ± 7.42 ng/mL, respectively. CONCLUSION: There was a significant increase in the serum, urine, and saliva levels of acyl ghrelin and des-acyl ghrelin without an increase in post-therapy body mass index in idiopathic generalized epilepsy patients.